183 related articles for article (PubMed ID: 16044135)
1. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia.
Cordonnier C; Maury S; Esperou H; Pautas C; Beaune J; Rodet M; Lagrange JL; Rouard H; Beaumont JL; Bassompierre F; Glückman E; Kuentz M; Durand-Zaleski I
Bone Marrow Transplant; 2005 Oct; 36(7):649-54. PubMed ID: 16044135
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
4. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
5. Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants.
Hill BT; Bolwell BJ; Rybicki L; Dean R; Kalaycio M; Pohlman B; Tench S; Sobecks R; Andresen S; Copelan E
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1738-46. PubMed ID: 20558313
[TBL] [Abstract][Full Text] [Related]
6. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
7. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation.
Meijer E; Dekker AW; Lokhorst HM; Petersen EJ; Nieuwenhuis HK; Verdonck LF
Transpl Infect Dis; 2004 Dec; 6(4):171-8. PubMed ID: 15762935
[TBL] [Abstract][Full Text] [Related]
8. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
9. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
Majhail NS; Mothukuri JM; Brunstein CG; Weisdorf DJ
Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need.
Shimoni A; Nagler A
Best Pract Res Clin Haematol; 2011 Sep; 24(3):369-79. PubMed ID: 21925090
[TBL] [Abstract][Full Text] [Related]
11. [The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation].
Groot MT; van Agthoven M; Löwenberg B; Willemze R; Uyl-de Groot CA
Ned Tijdschr Geneeskd; 2004 Mar; 148(10):480-4. PubMed ID: 15042895
[TBL] [Abstract][Full Text] [Related]
12. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
Schmid C; Schleuning M; Hentrich M; Markl GE; Gerbitz A; Tischer J; Ledderose G; Oruzio D; Hiddemann W; Kolb HJ
Bone Marrow Transplant; 2008 Apr; 41(8):721-7. PubMed ID: 18176613
[TBL] [Abstract][Full Text] [Related]
13. The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.
Cook G; Clark RE; Crawley C; Mackinnon S; Russell N; Thomson K; Pearce RM; Towlson K; Marks DI
Biol Blood Marrow Transplant; 2006 Mar; 12(3):293-300. PubMed ID: 16503498
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
15. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia.
van Agthoven M; Groot MT; Verdonck LF; Löwenberg B; Schattenberg AV; Oudshoorn M; Hagenbeek A; Cornelissen JJ; Uyl-de Groot CA; Willemze R
Bone Marrow Transplant; 2002 Aug; 30(4):243-51. PubMed ID: 12203141
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation.
Graef T; Vaupel M; Fenk R; Ruf L; Zohren F; Germing U; Haas R; Kobbe G
Hematol Oncol; 2007 Dec; 25(4):170-7. PubMed ID: 17579887
[TBL] [Abstract][Full Text] [Related]
17. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
Martins C; Lacerda JF; Lourenço F; Carmo JA; Lacerda JM
Acta Med Port; 2005; 18(5):329-37. PubMed ID: 16611537
[TBL] [Abstract][Full Text] [Related]
18. [Non-myeloablative allogeneic stem cell transplantation].
Dalgaard J; Fløisand Y; Stenersen M; Egeland T; Brinch L
Tidsskr Nor Laegeforen; 2007 Mar; 127(6):721-4. PubMed ID: 17363982
[TBL] [Abstract][Full Text] [Related]
19. Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission.
Martino R; Valcárcel D; Brunet S; Sureda A; Sierra J
Bone Marrow Transplant; 2008 Jan; 41(1):33-8. PubMed ID: 17982504
[TBL] [Abstract][Full Text] [Related]
20. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A
Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]